This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, reproduction and adaptation in any medium and for any purpose provided that it is properly attributed. For attribution, the original author(s), title, publication source (PeerJ PrePrints) and either DOI or URL of the article must be cited.
The GCTF-PRO seeks to examine the extent gastric cancer patients are tapping into new information particularly outside of conventional healthcare disclosures. Its significance is in assessing dimensions of QOL paradigms that frame statistical power using predictive methods. It seeks to embed evidence-based theories (perceptual and cognitive) to awareness levels in an attempt to bridge the biotechnological advances with prognostic/ diagnostic-related patient satisfactions. At present, it may complement existing GC QOL instruments and offer a novel approach on how cellular level prognoses could possibly correlate with QOL measures.
This is a draft proposal for a QOL measure I haven't had time to action. Any feedback would be much appreciated.